Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what’s new and why it matters in just 5 minutes.

Catch up on the day’s biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Get the inside stories

Get an insider’s guide to the new White House with Axios Sneak Peek. Sign up for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

A patient in the red zone of a COVID-19 ward at an emergency clinical hospital in Volgograd, Russia. Photo: Dmitry Rogulin/TASS via Getty Images

The World Health Organization (WHO) announced Friday that it has recommended two new drugs to treat COVID.

Why it matters: The recommendations come as cases spike around the world, and could especially serve lower-income countries that have struggled to contain the disease due to lack of vaccines and other medical necessities.

Details: WHO strongly recommends baricitinib, an oral drug typically used to treat rheumatoid arthritis, for patients with severe or critical symptoms. Administering it with corticosteroids is recommended.

  • WHO is also conditionally recommending use of the monoclonal antibody drug sotrovimab for treating mild or moderate symptoms in patients at high risk of hospitalization, including patients who are older, immunocompromised and unvaccinated.
  • “The extent to which these medicines will save lives depends on how widely available and affordable they will be,” the organization said in a release.
  • The recommendations are based on evidence from seven trials involving over 4,000 patients who exhibited a wide range of COVID symptoms.

Worth noting: WHO said it is working to “secure global supply capacity and equitable and sustainable access to the newly recommended therapeutics.”

Axios

Read Source